MiNK Therapeutics’ iNKT Cell Therap Achieves Complete Remission in Metastatic Testicular Cancer Patient

MiNK Therapeutics (NASDAQ: INKT) announced a complete remission in a patient with metastatic testicular cancer treated with its allogeneic iNKT cell therapy, agenT-797.

Findings published in Nature’s Oncogene detail how a single infusion of agenT-797, given alongside nivolumab, led to a complete clinical, radiologic, and biochemical remission. This remarkable outcome occurred in a patient who had previously failed multiple treatments, including platinum-based chemotherapy, stem cell transplant, and various immune checkpoint inhibitors. The publication notes the patient has shown no evidence of disease for over two years since treatment. The therapy was reportedly well-tolerated, with no cytokine release syndrome or graft-versus-host disease, and donor iNKT cells remained detectable for up to six months post-infusion.

This case further strengthens MiNK’s growing clinical evidence for agenT-797’s potential in solid tumors. The company recently presented data from its Phase 2 trial in second-line gastric cancer at the 2025 inaugural AACR Immuno-Oncology meeting, which showed immune activation and extended survival beyond 12 months in several patients previously resistant to checkpoint inhibitors.

MiNK Therapeutics is advancing agenT-797 as an off-the-shelf, cryopreserved iNKT cell therapy for a range of conditions, including graft-versus-host disease, solid tumors, and severe pulmonary inflammation. The company continues to enroll patients in its ongoing Phase 2 trial in gastric cancer, with more results anticipated in the coming months.